Skip to NavigationSkip to content


Immune system influences immunotherapy effectiveness, research shows

Image Credit: Piotrus

Preliminary research conducted at the University of Pittsburgh Cancer Institute (UPCI) has discovered a link between levels of certain immune cells in the body and the effectiveness of immunotherapy in patients.

The findings are based on results from the Checkmate 141 Phase 3 trial where Opdivo (nivolumab) proved itself to significant improve survival rates with fewer side effects in recurrent head and neck cancer patients. Despite the drug’s overall efficacy, it proved less effective in some patients than others.

Roche’s Tecentriq meets primary endpoints in Phase III lung cancer trial

Roche has presented new Phase III data for cancer immunotherapy Tecentriq (atezolizumab), which shows a clinically meaningful improvement in overall survival compared with docetaxel chemotherapy in people with locally advanced or metastatic non-small cell lung cancer.

Opdivo shows biggest survival increase for head and neck cancer in 20 years in Phase III trials

Opdivo (nivolumab) showed the biggest increase in survival for patients with head and neck cancer for 20 years, according to new Phase III clinical trial data presented by Bristol-Myers Squibb (NYSE: BMS) at the American Association for Cancer Research congress.

FDA approves new uses for BMS’ Opdivo/Yervoy cancer combo

FDA building

The FDA has granted Bristol Myers Squibb an expanded indication for its two-cancer drug regimen Opdivo and Yervoy, to treat patients with BRAF V600 wild-type and BRAF V600 mutation-positive unresectable or metastatic melanoma.

This approval expands the original indication for the Opdivo (nivolumab) and Yervoy (ipilimumab) regimen for the treatment of patients with BRAF V600 wild-type unresectable or metastatic melanoma to include patients, regardless of BRAF mutational status.

NICE ‘yes’ for BMS skin cancer drug Opdivo


NICE has approved Bristol-Myers Squibb’s skin cancer immunotherapy Opdivo (nivolumab) in final draft guidance as monotherapy for NHS patients in England and Wales.

The guidance recommends that the drug is made available with NHS funding for people with advanced melanoma – the most dangerous form of skin cancer. In 2012, some 13,500 people were diagnosed in the UK and approximately 2,100 people died from the disease.

NICE rejects BMS cancer drug in draft guidance

NHS sign
NICE says Opdivo cannot be considered a cost-effective use of NHS money

In draft guidance, NICE has chosen not to recommend Bristol-Myers Squibb’s Opdivo for the treatment of locally advanced or metastatic squamous non-small-cell lung cancer after prior chemotherapy in adults. 

While the NICE Committee recognised the clinical efficacy of Opdivo (nivolumab) in previously-treated squamous non-small-cell lung cancer (NSCLC), as well as its innovative nature and the fact that the drug met the criteria to be considered a life-extending, end-of-life treatment, the Institute did not consider it a cost-effective use of NHS resources.

Bristol-Myers Squibb notches kidney cancer first with Opdivo


Bristol-Myers Squibb has announced positive results from a Phase III study comparing Opdivo to Afinitor, the Novartis treatment that is a current standard therapy in advanced kidney cancer.

All patients in the study, named CheckMate -025, had received prior treatment for their cancer. The study included more than 800 people with renal cell carcinoma. Patients were randomised to receive either Opdivo (nivolumab) every two weeks or Afinitor (everolimus) once daily. The primary endpoint was overall survival. 

FDA grants Opdivo breakthrough status for kidney cancer


The FDA has given Bristol-Myers Squibb’s immuno-oncology drug Opdivo Breakthrough Therapy Designation as a kidney cancer treatment.

The FDA’s decision is based on data from BMS’ CheckMate series of studies of Opdivo (nivolumab). The studies have marked the earliest any checkpoint inhibitor has proven itself in a kidney cancer trial. The drug met its primary endpoint by demonstrating an overall survival benefit in patients with metastatic renal cell carcinoma (RCC).

BMS to trial Opdivo in solid tumours

BMS will explore the potential of Opdivo for solid tumours

Bristol-Myers Squibb will begin early-phase trials of its immuno-oncology treatment Opdivo with other cancer treatments, to see if the combination can treat people with advanced solid tumours.

BMS it teaming up with the Japanese biopharma firm Kyowa Hakko Kirin to study Opdivo (nivolumab) in combination with Kyowa’s anti-cancer treatment Poteligeo (mogamulizumab).

BMS’ Opdivo improves lung cancer survival

Two Phase III trials have found Opdivo improves lung cancer survival

A Phase III trial of Bristol-Myers Squibb’s immunotherapy Opdivo has found it increases overall survival in people with a common form of lung cancer.

The CHECKMATE-057 trial, presented at the American Society of Clinical Oncology conference in Chicago, found that Opdivo (nivolumab) - a drug in a new class of cancer immunotherapy treatments - improved survival in non squamous non-small cell lung cancer (non-SQ NSCLC) more than chemotherapy. 

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches